Rory de Vries, a virologist, recently faced the cancellation of funding for his research on antiviral treatments due to changes in the Trump administration. He shared the challenges posed to his team, including potential job losses and compliance with Dutch employment law. With funding only viable for about six more months, he is seeking alternative funding sources from the Dutch government or EU. The long-term viability of his promising research on respiratory viruses, including Covid-19, remains uncertain amidst these financial challenges.
Of the 20 members in his group, he will soon run out of money to pay the salaries for four. As of June, he estimated that his team has enough to keep going for about six months in its current form if it draws money from other funding sources.
The news, which he received in March, left him with a cascade of questions: What would happen to the doctoral student he had just hired for his project, a top candidate plucked from a pool of some 300 aspiring scientists?
Collection
[
|
...
]